MASTERKEY-265: T-VEC + Pembrolizumab Safe, Active in Unresectable Stage IIIB/IV Melanoma

June 3-7, 2016; Chicago, Illinois
Small phase Ib trial demonstrated that combination treatment with T-VEC plus pembrolizumab in advanced unresectable melanoma yields ORR of 57% and CR of 24%.
Format: Microsoft PowerPoint (.ppt)
File Size: 545 KB
Released: June 6, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Downloadable slideset on the role of biomarker testing and practical information on the use of targeted therapies in NSCLC for oncology nurses, from Clinical Care Options (CCO).

person default Beth Sandy, MSN, CRNP Elizabeth S. Waxman, BSN, MSN, ANP-BC Released: September 20, 2022

From Clinical Care Options (CCO), download slides reviewing contemporary systemic therapy for HCC and BTC

James M. Cleary, MD, PhD Mark Yarchoan, MD Released: September 19, 2022

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care

Jesús G. Berdeja, MD Caron A. Jacobson, MD Released: September 12, 2022

Video featuring Courtney R. Arn, APRN-CNP, discussing the latest evidence on individualizing treatment for gynecologic cancers, from Clinical Care Options (CCO)

person default Courtney Arn, CNP Registered Nurses: 1.0 Nursing contact hour Released: September 2, 2022 Expired: September 1, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings